Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravitreal Zimura (avacincaptad pegol) for geographic atrophy secondary to age-related macular degeneration
2020-000676-38Phase 3Unknown
- Sponsor
- IVERIC bio
- Start
- Mar 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avacincaptad pegol in age-related macular degeneration (AMD) (2 arms), sponsored by IVERIC bio. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
avacincaptad pegol
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2020-000676-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000676-38.